SC-43 (10-30 mg/kg; oral gavage; daily; for 23 days; male NCr athymic nude mice) treatment exhibits xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation[1]. Animal Model: Male NCr athymic nude mice (5-7 weeks of age) injected with HuCCT-1 cells[1] Dosage: 10 mg/kg or 30 mg/kg Administration: Oral gavage; daily; for 23 days Result: Exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation.
In Vitro
SC-43 (0-10 μM; 24-72 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment reveals the anti-proliferative effects in cholangiocarcinoma (CCA) cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively[1]. SC-43 (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment shows increased sub-G1 cells and G2-M arrest, indicating SC-43 induced differential apoptotic effects in these cell lines[1]. SC-43 (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment demonstrates significant increase in cleaved caspase-3 and PARP level[1]. SC-43 activates SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation. SC-43 augments SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition[1]. Cell Viability Assay[1] Cell Line: HuCCT-1, KKU-100, and CGCCA cells Concentration: 0 μM, 0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2.5 μM, 5 μM, 10 μM Incubation Time: 24 hours, 48 hours, 72 hours Result: Revealed the anti-proliferative effects in CCA cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively. Cell Cycle Analysis[1] Cell Line: HuCCT-1, KKU-100, and CGCCA cells Concentration: 0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM Incubation Time: 24 hours Result: Showed increased sub-G1 cells and G2-M arrest. Western Blot Analysis[1] Cell Line: HuCCT-1, KKU-100, and CGCCA cells Concentration: 0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM Incubation Time: 24 hours Result: Demonstrated significant increase in cleaved caspase-3 and PARP level.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Ming-Hung Hu, et al. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8(39):65077-65089.
[2]. Tung-Hung Su, et al. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep. 2017 May 11;7(1):1728.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
